Ipca Laboratories Limited (NSE: IPCALAB) reported Revenue from Operations for Q3 FY23 of ₹1,546 Crore up from ₹1,430.47 Crore year on year, a growth of 8%. The Consolidated Net Profit of ₹107.84 Crore, down 45% from ₹196.96 Crore in the same quarter of the previous year. The Earnings per Share is ₹4.25 for this quarter.
Ipca Laboratories Limited Q3 FY23; Revenue Increased To ₹1,546 Crore
Tags: pharmaceuticals
Related Post
- Pyramid Technoplast Limited reports Q3 FY26 volume-led growth; margins steady as new capacities ramp up
Pyramid Technoplast Limited (NSE: PYRAMID, BSE: 543969) reported moderate revenue growth in the December quarter,…
-
Dilip Buildcon Limited (NSE: DBL, BSE: 540047) reports Q3 FY26 results as order book hits record high
Dilip Buildcon Limited (NSE: DBL, BSE: 540047) reported its financial results for the quarter and…
-
Edelweiss Financial Services Limited charts multi-year growth across asset management and insurance businesses
Edelweiss Financial Services Limited (NSE: EDELWEISS, BSE: 532922) presented a multi-year snapshot of growth across…